654-2 加思密达减少红霉素胃肠道反应的观察及护理

Combined Using of 654-2 and Smecta in Alleviating Gastroenteric Adverse Reactions of Erythromycin: A Nursing Observation

目的 探讨654-2加用思密达来达到减少红霉素的胃肠道反应的临床应用价值。方法 将2001年1月至2002年10月共收治的可评价的因呼吸道感染而住院用红霉素静滴的患者100例,随机分为对照组、治疗组(1)、治疗组(2),对照组按10％葡萄糖+红霉素25～35mg/(kg·d)+VitB_6 50～100 mg/d。治疗组(1)在对照组基础上加服1包思密达于静滴前0.5～1 h,治疗组(2)在治疗组(1)的基础上加654-2按0.1～0.2 mg/(kg·d)于静滴补液中.观察3组患者胃肠道反应情况。结果 2组治疗组和对照组间疗效差异显著(P<0.01)。结论 654-2与思密达联合用药及精心护理,明显减轻了红霉素胃肠道反应副作用,促进了红霉素在临床上的应用。

objective To investigate the effect of combined use of 654～2 and smecta on alleviating erythromycin-induced gastroenteric symptoms. Methods 100 patients suffering from bronchoalveolitis who received erythromycin treatment from Jan. 2001 to Oct. 2002 were randomly divided into three groups. Patients of control group were given erythromycin,25～35 mg/( kg. d) iv gtt and VitB_6 50～100 mg/d, iv gtt. Patients of treatment group Ⅰ were given a bag of Smecta 0.5～1 h before erythromycin administra tion. Patients of treatment group Ⅱ received smecta as treatment group Ⅰ plus 654-2, 0.1～0.2 mg/( kg.d),iv gtt. The degree of gastroenteric adverse reactions was assessed. Results There was significant difference between control group and the other two treatment groups. ( P<0.01 ). Conclusion Combined treatment with 654-2 and smecta could alleviate the adverse reactions of erythromycin, thus promoting erythromycin use in clinical practice.